Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

The dal-HEART Program:
Dalcetrapib HDL Evaluation, Atherosclerosis,
and Reverse Cholesterol Transport
dal-VESSEL
450 patients with
CHD or CHD risk
equivalent
To evaluate the
effect of
dalcetrapib on
endothelial
function and BP,
measured by
FMD and ABPM
dal-PLAQuE
130 patients with
CHD
To evaluate the
effect
of dalcetrapib
on
inflammation,
plaque
size, and burden,
measured by
PET/CT and MRI
scans
dal-PLAQUE 2
900 patients
with CAD
To evaluate the
effect of
dalcetrapib on
CVD
progression,
assessed by
IVUS
and carotid Bmode
ultrasound
dal- ACUTE
300 patients
with ACS
To evaluate
the safety and
efficacy of
dalcetrapib in
patients
hospitalized for
ACS. Treatment
initiated within
1 week a nd
last for 20
weeks
ACS=acute coronary syndrome; FMD=flow-mediated dilation; ABPM=ambulatory blood pressure monitoring;
CAD=coronary artery disease; IVUS=intravascular ultrasound; PET=positron emission tomography;
CT=computed tomography; MRI=magnetic resonance
Schwartz GG, et al. Amer. Heart J. 2009;158:896-901
55